Company intelligence / Profile preview

DAYLI Partners

Seoul, Seoul, South Koreadayli.partners ↗

Ownership: Private
Employees: ~40
Development stage: Other

Overview

DAYLI Partners is one of South Korea’s most active healthcare-focused venture capital firms. It manages over 500 billion KRW (~$360M USD) in assets and specializes in early-stage to growth-stage investments across therapeutics, diagnostics, medical devices, digital health and fintech. The firm has supported numerous innovative biotech startups developing next-generation therapies and technologies for cancer and other major indications.

Therapeutic areas: OncologyRare DiseasesImmunologyOther
Modalities: Small moleculeMonoclonal antibodyCell therapyAntibody-drug conjugateMedical device
Industry: Investors

Partnerships

Collaborates widely within Korean biotech ecosystem; Portfolio company partnerships with academic institutions (e.g., Johns Hopkins School of Medicine) and large pharma

Beyond the preview

Go deeper on DAYLI Partners.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DAYLI Partners.

Explore the full profile